# Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally

> **NCT00489931** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 44 (—)

## Conditions studied

- Influenza A Virus, H5N1 Subtype
- Influenza A Virus
- Influenzavirus A
- Orthomyxovirdae
- H5N1 Virus

## Interventions

- **DRUG:** VRC-AVIDNA036-00-VP

## Key facts

- **NCT ID:** NCT00489931
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06-18
- **Primary completion:** —
- **Final completion:** 2009-04-15
- **Target enrollment:** 44 (—)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00489931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00489931, "Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00489931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*